Beam Therapeutics Inc logo

BEAM

Beam Therapeutics Inc

$46.19

Earnings Summary

Revenue
$0.01Mn
Net Profits
$-201.56Mn
Net Profit Margins
-3359333.33%

Highlights

Revenue:

Beam Therapeutics Inc’s revenue jumped 0% since last year same period to $0.01Mn in the Q1 2021. On a quarterly growth basis, Beam Therapeutics Inc has generated 0% jump in its revenue since last 3-months.

Net Profits:

Beam Therapeutics Inc’s net profit fell -561.76% since last year same period to $-201.56Mn in the Q1 2021. On a quarterly growth basis, Beam Therapeutics Inc has generated -111.14% fall in its net profits since last 3-months.

Net Profit Margins:

Beam Therapeutics Inc’s net profit margin fell -561.76% since last year same period to -3359333.33% in the Q1 2021. On a quarterly growth basis, Beam Therapeutics Inc has generated -111.14% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Beam Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.32
EPS Estimate Current Year
-1.32

Highlights

EPS Estimate Current Quarter:

Beam Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.32 - a -3.13% fall from last quarter’s estimates.

EPS Estimate Current Year:

Beam Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.32.

Key Ratios

Key ratios of the Beam Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-1.02
Return on Assets (ROA)
-0.08
Return on Equity (ROE)
-0.4

Highlights

Earning Per Share (EPS):

Beam Therapeutics Inc’s earning per share (EPS) jumped 17.07% since last year same period to -1.02 in the Q2 2022. This indicates that the Beam Therapeutics Inc has generated 17.07% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Beam Therapeutics Inc’s return on assets (ROA) stands at -0.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Beam Therapeutics Inc’s return on equity (ROE) stands at -0.4.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-09
-1.12
-1.02
8.93%
2022-05-09
-0.89
-1.01
-13.25%

Company Information

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Organisation
Beam Therapeutics Inc
Headquarters
238 Main Street, Cambridge, MA, United States, 02142
Employees
507
Industry
Health Technology
CEO
John M. Evans

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*